xarelto birchfield 250x140 Beasley Allen lawyer Andy Birchfield appointed to leadership role in Xarelto blood thinner multidistrict litigationMONTGOMERY, ALA. (February 10, 2015) – Andy D. Birchfield, Jr., Principal & Mass Torts Section Head at Beasley, Allen, Crow, Methvin, Portis & Miles, P.C., has been named Co-Lead Counsel for the Plaintiffs Steering Committee (PSC) in the multidistrict litigation (MDL) surrounding blood thinner medication Xarelto. He was appointed by U.S. District Judge Eldon E. Fallon, who is overseeing the MDL in United States District Court, Eastern District of Louisiana. Nearly two dozen lawsuits filed against Johnson & Johnson subsidiary Janssen Pharmaceuticals and Bayer Corp. were consolidated in Louisiana federal court in December. Xarelto has been linked to serious side effects including internal bleeding, gastrointestinal bleeding, brain bleed and death.

“This is important litigation involving very serious injuries to thousands of individuals. Judge Fallon has appointed a group of excellent lawyers to serve on the Plaintiffs Steering Committee, and I am honored to be in a leadership position. Together, we look forward to advancing the cause of those injured by this prescription drug,” Birchfield said.

Xarelto is a novel oral anticoagulant approved in the United States for six indications including reducing the risk of stroke in patients with nonvalvular atrial fibrillation; treating deep vein thrombosis and pulmonary embolism, and reducing the recurrence of these conditions; and preventing blood clots in patients following knee or hip replacement surgery. The Xarelto lawsuits follow a recent $650 million settlement related to another blood-thinning drug, Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals. Pradaxa was linked to more than 500 bleeding deaths.

Judge Fallon presided over litigation against Merck & Co. related to its painkiller Vioxx. Birchfield was chosen as Co-Lead Counsel for the Vioxx Litigation MDL PSC in 2005. He was lead counsel or co-lead counsel in five Vioxx trials, including one that resulted in a $51 million verdict against Merck. In 2007, Merck agreed to a $4.85 billion settlement for Vioxx litigation.

The case is In Re: Xarelto (Rivaroxaban) Products Liability Litigaiton, Case 2:14-md-02592-EEF-MBN.



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

xarelto

Plaintiffs continue seeking justice over Xarelto...

Less than three years after Xarelto’s initial approval, the FDA issued black box warnings because of...
xarelto

New, contradictory evidence from Xarelto makers could...

There is an effective lab test to protect patients taking Xarelto, but that isn’t what jurors heard...
xarelto

Third Xarelto Trial Begins This Week

Last month, U.S. District Judge Eldon E. Fallon rejected the latest attempts by Xarelto makers to dodge...
xarelto

Recent studies confirm Xarelto bleeding risks, adverse...

There were 21,996 severe injuries reported involving anticoagulant drugs including 3,018 reported...
xarelto

Second Xarelto bellwether trial underway

The second bellwether trial involving bleeding risks with the blood thinner Xarelto is slated to begin...
xarelto

First Xarelto trial set for April; blood thinner...

The first of four bellwether trials for the Xarelto multidistrict litigation (MDL) is set to begin on...

Thank you for all your hard work

Thank you for all your hard work over the past years on my behalf and so many others. God bless you all.

—Ella